Compare Glenmark Pharma with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FDC LTD. - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FDC LTD. GLENMARK PHARMA/
FDC LTD.
 
P/E (TTM) x 15.7 18.8 83.7% View Chart
P/BV x 2.2 3.6 59.9% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 GLENMARK PHARMA   FDC LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
FDC LTD.
Mar-18
GLENMARK PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs712319 223.1%   
Low Rs484164 294.9%   
Sales per share (Unadj.) Rs349.661.6 567.2%  
Earnings per share (Unadj.) Rs32.89.9 329.5%  
Cash flow per share (Unadj.) Rs44.312.0 370.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.673.2 271.5%  
Shares outstanding (eoy) m282.17174.40 161.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.73.9 43.6%   
Avg P/E ratio x18.224.3 75.1%  
P/CF ratio (eoy) x13.520.2 66.8%  
Price / Book Value ratio x3.03.3 91.1%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62542,118 400.4%   
No. of employees `00012.05.5 217.6%   
Total wages/salary Rs m20,5612,167 948.9%   
Avg. sales/employee Rs Th8,196.01,943.7 421.7%   
Avg. wages/employee Rs Th1,708.1391.7 436.0%   
Avg. net profit/employee Rs Th768.5313.7 245.0%   
INCOME DATA
Net Sales Rs m98,65510,751 917.7%  
Other income Rs m2,081510 408.4%   
Total revenues Rs m100,73611,260 894.6%   
Gross profit Rs m15,8582,267 699.6%  
Depreciation Rs m3,259351 927.5%   
Interest Rs m3,34614 23,899.3%   
Profit before tax Rs m11,3352,411 470.1%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756671 559.7%   
Profit after tax Rs m9,2501,735 533.1%  
Gross profit margin %16.121.1 76.2%  
Effective tax rate %33.127.8 119.1%   
Net profit margin %9.416.1 58.1%  
BALANCE SHEET DATA
Current assets Rs m66,9687,213 928.5%   
Current liabilities Rs m40,2112,104 1,911.4%   
Net working cap to sales %27.147.5 57.1%  
Current ratio x1.73.4 48.6%  
Inventory Days Days8354 152.9%  
Debtors Days Days8128 292.9%  
Net fixed assets Rs m33,3226,865 485.4%   
Share capital Rs m282175 161.1%   
"Free" reserves Rs m55,77012,586 443.1%   
Net worth Rs m56,05212,761 439.2%   
Long term debt Rs m35,7386 595,625.0%   
Total assets Rs m132,88815,041 883.5%  
Interest coverage x4.4173.2 2.5%   
Debt to equity ratio x0.60 135,603.6%  
Sales to assets ratio x0.70.7 103.9%   
Return on assets %9.511.6 81.5%  
Return on equity %16.513.6 121.4%  
Return on capital %17.819.0 94.0%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9981,889 3,335.3%   
Fx outflow Rs m22,8590-   
Net fx Rs m40,1401,889 2,125.1%   
CASH FLOW
From Operations Rs m13,2421,498 883.7%  
From Investments Rs m-6,990201 -3,475.8%  
From Financial Activity Rs m-7,387-1,694 436.0%  
Net Cashflow Rs m-2,97110 -28,842.7%  

Share Holding

Indian Promoters % 48.3 68.9 70.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.7 146.8%  
FIIs % 34.4 7.5 458.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.0 55.3%  
Shareholders   56,727 23,730 239.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (3QFY20); Net Profit Up 67.7% (Quarterly Result Update)

Feb 10, 2020 | Updated on Feb 10, 2020

For the quarter ended December 2019, FDC LTD. has posted a net profit of Rs 733 m (up 67.7% YoY). Sales on the other hand came in at Rs 3 bn (up 26.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (2QFY20); Net Profit Up 45.4% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, FDC LTD. has posted a net profit of Rs 627 m (up 45.4% YoY). Sales on the other hand came in at Rs 3 bn (up 28.8% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS